[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002077176A3 - Aberrantly expressed proteins in laser capture microdissected tumors - Google Patents

Aberrantly expressed proteins in laser capture microdissected tumors Download PDF

Info

Publication number
WO2002077176A3
WO2002077176A3 PCT/US2002/008847 US0208847W WO02077176A3 WO 2002077176 A3 WO2002077176 A3 WO 2002077176A3 US 0208847 W US0208847 W US 0208847W WO 02077176 A3 WO02077176 A3 WO 02077176A3
Authority
WO
WIPO (PCT)
Prior art keywords
aberrantly expressed
expressed proteins
laser capture
fingerprints
capture microdissected
Prior art date
Application number
PCT/US2002/008847
Other languages
French (fr)
Other versions
WO2002077176A2 (en
Inventor
Emanuel Frank Petricoin Iii
Lance A Liotta
Michael R Emmert-Buck
Yingming Zhao
Original Assignee
Us Gov Health & Human Serv
Mt Sinai School Of Medicine
Emanuel Frank Petricoin Iii
Lance A Liotta
Michael R Emmert-Buck
Yingming Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Mt Sinai School Of Medicine, Emanuel Frank Petricoin Iii, Lance A Liotta, Michael R Emmert-Buck, Yingming Zhao filed Critical Us Gov Health & Human Serv
Priority to AU2002255880A priority Critical patent/AU2002255880A1/en
Publication of WO2002077176A2 publication Critical patent/WO2002077176A2/en
Publication of WO2002077176A3 publication Critical patent/WO2002077176A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Provided herein are specific examples of tumor or tumor-stage linked protein fingerprints and specific proteins identified from these fingerprints as being aberrantly expressed in specific diseased cell types. Methods of using these fingerprints, sub-sets thereof, and individual proteins in the diagnosis, prognosis, treatment, treatment selection, and drug development for disease are also provided.
PCT/US2002/008847 2001-03-22 2002-03-22 Aberrantly expressed proteins in laser capture microdissected tumors WO2002077176A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002255880A AU2002255880A1 (en) 2001-03-22 2002-03-22 Aberrantly expressed proteins in laser capture microdissected tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27804801P 2001-03-22 2001-03-22
US60/278,048 2001-03-22

Publications (2)

Publication Number Publication Date
WO2002077176A2 WO2002077176A2 (en) 2002-10-03
WO2002077176A3 true WO2002077176A3 (en) 2004-04-01

Family

ID=23063475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/008847 WO2002077176A2 (en) 2001-03-22 2002-03-22 Aberrantly expressed proteins in laser capture microdissected tumors

Country Status (2)

Country Link
AU (1) AU2002255880A1 (en)
WO (1) WO2002077176A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412026B (en) * 2002-02-07 2004-08-26 Illmensee Karl Dr METHOD FOR DIAGNOSING A CYSTIC OVARIAL CARCINOMA
ATE359516T1 (en) 2003-06-06 2007-05-15 Hoffmann La Roche USE OF THE PROTEIN CRABP II (CELLULAR RETINOIC ACID-BINDING PROTEIN II) AS A MARKER FOR BREAST CANCER
WO2005036180A1 (en) * 2003-10-08 2005-04-21 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Analysis methods using biomarkers concentrated with biomarkers attractant molecules
WO2005124357A1 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein elongation factor-1-alpha-1 as a marker for breast cancer
CA2567980A1 (en) 2004-06-21 2006-01-26 Exelixis, Inc. Acacs as modifiers of the igf pathway and methods of use
US20100173788A1 (en) * 2005-06-21 2010-07-08 Vermillion, Inc. Biomarkers for breast cancer
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
FR2894031A1 (en) * 2005-11-25 2007-06-01 Genome Express S A Sa METHOD FOR THE PRESERVATION OF THE PRESENCE OR ABSENCE OF MARKERS ASSOCIATED WITH THE CHEMOSENSITIVITY OF TUMORS
US20090175871A1 (en) * 2005-11-25 2009-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors
US8080428B2 (en) 2006-04-28 2011-12-20 Singapore Health Services Pte Ltd. Investigation of mucosa dryness conditions
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gabaculine or its analog in the manufacture of a medicament for treating hepatocellular carcinoma
CN100479863C (en) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Correlation of cofilin 1 and resistance to anticancer taxane chemotherapy medicine
WO2009009890A1 (en) * 2007-07-16 2009-01-22 University Health Network Ovarian cancer biomarkers
KR101431062B1 (en) 2012-03-08 2014-08-21 (주)바이오메디앙 Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same
AU2017214850B2 (en) 2016-02-04 2024-01-04 Immune System Key Ltd. Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
CN110031625A (en) * 2019-03-31 2019-07-19 苏州市立医院 Detection reagent and its application comprising 5 antibody of phosphoglucomutase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOISEEVA ET AL.: "Characterisation of the promoter which regulates expression of a phosphoglucomutase-related protein, a component of the dystrophin/utrophin cytoskeleton predominantly expressed in smooth muscle", EUR. J. BIOCHEM., vol. 248, 1997, pages 634 - 643, XP000982239 *

Also Published As

Publication number Publication date
WO2002077176A2 (en) 2002-10-03
AU2002255880A1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
EP2100614A3 (en) PDGFR-alpha antagonists for treatment of metastatic bone cancer
WO2003041562A3 (en) Molecular cancer diagnosis using tumor gene expression signature
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002057741A3 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2002062945A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002055735A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2005030266A3 (en) Optical imaging of colorectal cancer
WO2002040672A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004051269A3 (en) Ciz1 replication protein
EP1696028A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003069553A3 (en) Method of image analysis
WO2004083241A3 (en) Btc-interacting proteins and use thereof
WO2002077232A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
AU5618700A (en) Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP